Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097549 | 0.89 | CYP1A2 (0.56) | CYP1A2CYP2D6ARPTGS2TP53 | |
| SCHEMBL6095059 | 0.88 | CYP1A2 (0.56) | CYP1A2CYP2D6ARPTGS2TP53 | |
| SCHEMBL6096492 | 0.87 | CYP1A2 (0.54) | CYP1A2CYP2D6ARPTGS2TP53 | |
| SCHEMBL6097821 | 0.87 | CYP1A2 (0.81) | CYP1A2CYP2D6AR | |
| SCHEMBL6097555 | 0.87 | CYP1A2 (0.72) | CYP1A2CYP2D6ARTP53 | |
| SCHEMBL6098575 | 0.86 | CYP1A2 (0.53) | CYP1A2TP53 | |
| SCHEMBL6098897 | 0.85 | CYP1A2 (0.52) | CYP1A2CYP2D6PTGS2 | |
| SCHEMBL6096730 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP2D6AR | |
| SCHEMBL6095421 | 0.83 | CYP1A2 (0.50) | CYP1A2 | |
| SCHEMBL6098401 | 0.81 | CYP1A2 (0.48) | CYP1A2PTGS2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | CYP1A2 670/4885CYP2D6 801/4885AR 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.